KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) Amortization - Goodwill (2017 - 2024)

Teva Pharmaceutical Industries' Amortization - Goodwill history spans 6 years, with the latest figure at $280.0 million for Q4 2024.

  • For the quarter ending Q4 2024, Amortization - Goodwill changed N/A year-over-year to $280.0 million, compared with a TTM value of $280.0 million through Dec 2025, down 78.12%, and an annual FY2024 reading of $1.3 billion, up 82.86% over the prior year.
  • Amortization - Goodwill for Q4 2024 was $280.0 million at Teva Pharmaceutical Industries, down from $600.0 million in the prior quarter.
  • The five-year high for Amortization - Goodwill was $4.6 billion in Q3 2020, with the low at $280.0 million in Q4 2024.
  • Average Amortization - Goodwill over 4 years is $1.2 billion, with a median of $700.0 million recorded in 2023.
  • Year-over-year, Amortization - Goodwill fell 6.04% in 2023 and then crashed 42.86% in 2024.
  • Tracing TEVA's Amortization - Goodwill over 4 years: stood at $4.6 billion in 2020, then crashed by 82.71% to $800.0 million in 2022, then fell by 12.5% to $700.0 million in 2023, then plummeted by 60.0% to $280.0 million in 2024.
  • Per Business Quant, the three most recent readings for TEVA's Amortization - Goodwill are $280.0 million (Q4 2024), $600.0 million (Q3 2024), and $400.0 million (Q2 2024).